RxDoctor Payments Data

Howard Kerstein

Denver, CONPI 1184607012

Payments from drug & device makers

What this record shows

The money is spread across several categories — speaking fees (56.8%), consulting fees and food and beverage — rather than concentrated in one kind of arrangement. 23 manufacturers reported payments, led by Boehringer Ingelheim at 52.5% of the total.

$19,046in general payments, 2019–2025

Across 161 payments — averaging $118.30 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boehringer Ingelheim$10K
  • Lilly USA, LLC$4K
  • Novo Nordisk$2K
  • AstraZeneca$2K
  • Mannkind Corporation$206
  • Amneal Pharmaceuticals LLC$206
  • plus $837 from 17 others
$1,172in research payments, 2019–2025

Across 14 payments — averaging $83.71 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Gilead$1K

What the payments were for

  • Consulting fees$4,81525%
  • Speaking & faculty fees$10,81357%
  • Travel & lodging$9775%
  • Food & beverage$2,43313%
  • Education$80%

General payments by program year

19
20

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

Where these figures come from

Is this you, or does something look wrong? →